Senate Bill S3203, which would ban pay‑for‑delay arrangements that keep generics off the market, was reported to first reading after committee discussion about prevalence and patient impacts; sponsor named as Senator Fernandez.

For millions of Americans, the promises of modern medicine are starting to sound a lot like a scam. Despite breakthrough treatments and historic R&D investments, every year more and more people can’t…

Medication Safety is paramount. Explore how South Korea's pharmacy experts are championing safe drug use and affordable healthcare for all citizens. A must-read for global health advocates.

Patient-Led Survey Reveals Insurance Barriers and Personal Factors Contribute Significantly to Patient Affordability Concerns

Maryland seeks to establish upper payment limits to combat rising prescription drug costs.

SEA 80 limits fees and conditions for pharmacy benefit manager audits and disclosures.

The Senate Insurance Committee reported SB401 as amended on April 1, 2026. Sponsors said the board will gather manufacturer pricing data and recommend whether costs are justified; patient advocates warned the information could later be used to restrict access. A sunset and proprietary-data protections were added.